About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Safety Questions Persist for Some Drugs Despite Expedited Approvals by FDA

by Kathy Jones on October 31, 2013 at 8:27 PM
Font : A-A+

 Safety Questions Persist for Some Drugs Despite Expedited Approvals by FDA

A new study published in JAMA Internal Medicine reveals that the expedited reviews of new drugs that had been approved by the US Food and Drug Administration made use of fewer patients in their trials and some safety questions remained unanswered.

The FDA is authorized to make new drugs available more quickly if they would be a significant therapeutic advancement and if they fulfill unmet therapeutic needs for serious illnesses, according to the study background.

Thomas J. Moore, A.B., of the Institute for Safe Medication Practices, Alexandria, Va., and Curt D. Furberg, M.D., Ph.D., of the Wake Forest School of Medicine, Winston-Salem, N.C., examined development times, clinical testing, post-market follow-up and safety risks for the new drugs approved by the FDA in 2008, when most provisions of current law, regulation and policies were in effect.

Advertisement

That year, the FDA approved 20 therapeutic drugs (eight under expedited review and 12 under standard review). The study findings indicate that expedited drugs took a median (midpoint) of 5.1 years of clinical development to get marketing approval compared with 7.5 years for the drugs that underwent standard review, according to the study results.

The expedited drugs were tested for efficacy in a median 104 patients compared with a median 580 patients for standard review. By 2013, many postmarketing studies to gather additional evidence on the safety of expedited drugs had not been completed, according to researchers.

"The testing of new drugs has shifted from a situation in which most testing was conducted prior to initial approval to a situation in which many innovative drugs are more rapidly approved after a small trial in a narrower patient population with extensive additional testing conducted after approval," the authors conclude. "Our findings suggest that the shift has made it more difficult to balance the benefits and risks of new drugs. Further systematic assessment of the standards and procedures for testing new drugs is needed."
(JAMA Intern Med. Published online October 28, 2013. doi:10.1001/jamainternmed.2013.11813.

Editor''s Note: Please see article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.


Commentary: Can Expedited Drug Approval Without Expedited Follow-up Be Trusted?

In a related commentary, Daniel Carpenter, Ph.D., of Harvard University, Boston, writes: "The findings of Moore and Furberg underscore the continuing importance of rigorous premarket studies of ample size. If the critical phrase 'serious or life-threatening conditions that would address an unmet medical need'' is defined broadly enough (and there are lobbying efforts to define it as broadly as possible), the future of evidence for pharmaceuticals in the United States will look more like 100 patients for efficacy trials instead of 500 patients."

"If the FDA''s requirements for new drugs, both premarket and postmarket, are weakened, trust in both the efficacy and safety of prescription drugs is likely to be weakened. The stakes of the current policy debates could not be higher. There is scarcely a feature of the American health care system that does not depend on evidence-based trust in prescription drugs, ratified and enforced by the FDA," Carpenter concludes.
(JAMA Intern Med. Published online October 28, 2013. doi:10.1001/jamainternmed.2013.9202.

Editor''s Note: Please see article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.



Source: Newswise
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
First Dose of COVID-19 Vaccines May Improve Mental Health
Printed Temperature Sensors help with Continuous Temperature Monitoring
Health Benefits of Giloy
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Drugs Banned in India 

Recommended Reading
Drugs Banned in India
Several drugs are either banned or withdrawn after introduction in the market....
Chemotherapy Drugs
Chemotherapy drugs perform like 'magic bullets' to destroy cancer cells in the body....
Drugs Causing Low Blood Sodium Levels / Hyponatremia
Many drugs can lower your blood sodium levels or hyponatremia. Low blood sodium symptoms are ......
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use